Publication date: October 2019Source: Cancer Epidemiology, Volume 62Author(s): Maria A. Karalexi, Nick Dessypris, Jacqueline Clavel, Catherine Metayer, Friederike Erdmann, Laurent Orsi, Alice Y. Kang, Joachim Schüz, Audrey Bonaventure, Kathryn R. Greenop, Elizabeth Milne, Eleni Th. Petridou, NARECHEM-ST groupAbstractBackgroundDietary habits during pregnancy have been inconsistently linked to childhood acute myeloid leukemia (AML), given the putative intrauterine onset of the disease as a result of...
Mark above section as read
Oncogenic K‐RAS has been difficult to target and currently there is no K‐RAS‐based targeted therapy available for patients suffering from K‐RAS‐driven lung adenocarcinoma (AC). Alternatively, targeting K‐RAS‐downstream effectors, K‐RAS‐cooperating signaling pathways or cancer hallmarks, such as tumor‐promoting inflammation, has been shown to be a promising therapeutic strategy. Since the JAK‐STAT pathway is considered to be a central player in inflammation‐mediated tumorigenesis, we investigated...
There have been hints that non‐viral cancer antigens are differentially expressed in Human Papillomavirus (HPV) positive and HPV‐negative head and neck squamous cell carcinoma (HNSCC). Antibody responses (AR) to cancer antigens may be used to indirectly determine cancer antigen expression in the tumor using a non‐invasive and tissue‐saving liquid biopsy. Here, we set out to characterize AR to a panel of non‐viral cancer antigens in HPV‐positive and HPV‐negative HNSCC patients. A fluorescent microbead...
Mark above section as read
Cancers, Vol. 11, Pages 1162: A Role for the WNT Co-Receptor LRP6 in Pathogenesis and Therapy of Epithelial Cancers Cancers doi: 10.3390/cancers11081162 Authors: Raisch Côté-Biron Rivard The WNT/β-catenin signaling pathway controls stem and progenitor cell proliferation, survival and differentiation in epithelial tissues. Aberrant stimulation of this pathway is therefore frequently observed in cancers from epithelial origin. For instance, colorectal and hepatic cancers...
Cancers, Vol. 11, Pages 1163: Tailor-Made Detection of Individual Phosphorylated and Non-Phosphorylated EPIYA-Motifs of Helicobacter pylori Oncoprotein CagA Cancers doi: 10.3390/cancers11081163 Authors: Pachathundikandi Gutiérrez-Escobar Tegtmeyer The gastric pathogen and carcinogen Helicobacter pylori (H. pylori) encodes a type IV secretion system for translocation of the effector protein CagA into host cells. Injected CagA becomes tyrosine-phosphorylated at the five amino...
Cancers, Vol. 11, Pages 1161: Interactions of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) with the Immune System: Implications for Inflammation and Cancer Cancers doi: 10.3390/cancers11081161 Authors: Beyer Baukloh Stoyanova Kamphues Sattler Kotsch Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily. TRAIL has historically been distinct from the Fas ligand and TNFα in terms of selective...
Cancers, Vol. 11, Pages 1160: Mutation in DNA Polymerase Beta Causes Spontaneous Chromosomal Instability and Inflammation-Associated Carcinogenesis in Mice Cancers doi: 10.3390/cancers11081160 Authors: Shengyuan Zhao Alex W. Klattenhoff Megha Thakur Manu Sebastian Dawit Kidane DNA polymerase beta (Pol β) is a key enzyme in the base excision repair (BER) pathway. Pol β is mutated in approximately 40% of human tumors in small-scale studies. The 5´-deoxyribose-5-phosphate...
Cancers, Vol. 11, Pages 1164: Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers
Cancers, Vol. 11, Pages 1164: Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers Cancers doi: 10.3390/cancers11081164 Authors: Jacobson Munding Hayden Levy Kuzel Pappas Masood Room for improvement exists regarding recommendations for screening, staging, therapy selection, and frequency of surveillance of gastrointestinal cancers. Screening is costly and invasive, improved staging demands increased sensitivity and specificity to better guide...
Cancers, Vol. 11, Pages 1159: Coordinated Expression of Ras Suppressor 1 (RSU-1) and Growth Differentiation Factor 15 (GDF15) Affects Glioma Cell Invasion Cancers doi: 10.3390/cancers11081159 Authors: Maria Louca Vasiliki Gkretsi Triantafyllos Stylianopoulos Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor due to its invasive phenotype. Ras suppressor 1 (RSU-1) is a cell-extracellular matrix adhesion protein and we recently found that it promotes cell invasion...
Mark above section as read
Ubiquitin E3 ligase CUL4A plays important oncogenic roles in the development of cancers. DTL, one of the CUL4-DDB1 associated factors (DCAFs), may involve in the process of cancer development. Programmed cell ...
Mark above section as read
Abstract Cervical carcinogenesis, the second leading cause of cancer death in women worldwide, is caused by multiple types of human papillomaviruses (HPVs). To investigate a possible role for HPV in a cervical carcinoma that was HPV‐negative by PCR testing, we performed HPV DNA hybridization capture plus massively parallel sequencing. This detected a subgenomic, URR‐E6‐E7‐E1 segment of HPV70 DNA, a type not generally associated with cervical cancer, inserted in an intron of the B‐cell lymphoma/leukemia...
Mark above section as read
Publication date: September 2019Source: European Journal of Cancer, Volume 119Author(s): Ahmed Mekki, Laurent Dercle, Philip Lichtenstein, Ghaida Nasser, Aurélien Marabelle, Stéphane Champiat, Emilie Chouzenoux, Corinne Balleyguier, Samy AmmariAbstractPurposeNew-onset pituitary gland lesions are observed in up to 18% of cancer patients undergoing treatment with immune checkpoint blockers (ICB). We aimed to develop and validate an imaging-based decision-making algorithm for use by the clinician that...
Publication date: September 2019Source: European Journal of Cancer, Volume 119Author(s): Claire Gallois, Pascal Artru, Astrid Lièvre, Edouard Auclin, Thierry Lecomte, Christophe Locher, Lysiane Marthey, Yosra Zaimi, Roger Faroux, Simon Pernot, Maximilien Barret, Julien TaiebAbstractIntroductionThe Patient-Generated Subjective Global Assessment (PG-SGA) is currently the standard nutritional assessment tool for patients with cancer. In a retrospective assessment of a prospective cohort, we showed that...
Mark above section as read
Future Oncology, Ahead of Print.
Mark above section as read
Publication date: Available online 12 August 2019Source: Critical Reviews in Oncology/HematologyAuthor(s): Julia Hippisley-Cox
Publication date: Available online 12 August 2019Source: Critical Reviews in Oncology/HematologyAuthor(s): Rongrong Dong, Jiali Ji, Hong Liu, Xuexin HeAbstractApproximately 30-50% of advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer patients will develop brain metastases (BMs) during the disease course. Brain metastases may become a main limitation of life expectancy and a half of them will die from brain progression. Even in patients with early HER2-positive breast...
Mark above section as read
Purpose: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of high-grade serous ovarian cancers (HGSOCs). Therapeutic resistance, resulting from restoration of homologous recombination (HR) repair or replication fork stabilization, is a pressing clinical problem. We assessed the activity of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor known to cause replication catastrophe, as monotherapy and in combination with the PARP inhibitor olaparib in preclinical models...
Purpose:Invasive lobular carcinoma (ILC) is a subtype of breast cancer accounting for 10% of breast tumors. The majority of patients are treated with endocrine therapy; however, endocrine resistance is common in ER-positive breast cancer and new therapeutic strategies are needed. Bromodomain and extra-terminal inhibitors (BETi) are effective in diverse types of breast cancer but they have not yet been assessed in ILC. Experimental Design:We assessed whether targeting the BET proteins with JQ1 could...
Purpose: Combination strategies leveraging chemotherapeutic agents and immunotherapy have held the promise as a method to improve benefit to cancer patients. However, most chemotherapies have detrimental effects on immune homeostasis and differ in their ability to induce immunogenic cell death. The approval of pemetrexed and carboplatin with anti-PD-1 (pembrolizumab) for treatment of non-small cell lung cancer, represents the first approved chemotherapy and immunotherapy combination. Although the...
Purpose: Irinotecan and topotecan are used to treat a variety of different cancers. However, they have limitations including chemical instability and severe side effects. To overcome these limitations, we developed the clinical indenoisoquinolines: LMP400 (indotecan), LMP776 (Indimitecan) and LMP744. The purpose of the study is to build the molecular rationale for phase 2 clinical trials. Experimental Design: CellMinerCDB (http://discover.nci.nih.gov/cellminercdb) was used to mine the cancer cell...
Purpose: Histone deacetylase inhibitors (HDACi) enhance tumor immunogenicity through several mechanisms and may improve response to immune checkpoint inhibitors (ICIs). In a phase 1/1b trial, we tested the oral HDACi vorinostat combined with the programmed cell death protein 1 inhibitor pembrolizumab in advanced/metastatic non-small cell lung cancer (NSCLC). Experimental Design: Patients received intravenous pembrolizumab (200 mg every 3 weeks) plus oral vorinostat (200 or 400 mg/day). Primary endpoint...
Mark above section as read
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and it is the third leading cause of cancer-related deaths worldwide. Recently, aberrant signaling through the fibroblast growth factor 19 (FGF19) / fibroblast growth factor receptor 4 (FGFR4) axis has been implicated in HCC. Here, we describe the development of FGF401, a highly potent and selective, first in class, reversible-covalent small-molecule inhibitor of the kinase activity of FGFR4. FGF401 is exquisitely selective...
Mark above section as read
Abstract In response to the complexity of medical care in oncology, 2 years ago, we designed a new teaching method (SPOC, Small Private Online Course) to improve cancer treatment and its management by emphasizing the community-hospital interface. The educational objective of this study was to evaluate after 1 year if the interest for this teaching remained constant over the long term to meet both educational and financial requirements. We designed a questionnaire including 18 questions...
Mark above section as read
Publication date: Available online 12 August 2019Source: European Journal of Surgical OncologyAuthor(s): Takuma Iwai, Takeshi Yamada, Goro Takahashi, Kohki Takeda, Michihiro Koizumi, Seiichi Shinji, Akihisa Matsuda, Yasuyuki Yokoyama, Keisuke Hara, Kohji Ueda, Ryo Ohta, Nobuhiko Taniai, Hiroshi YoshidaAbstractIntroductionMost patients with colorectal liver metastases, who undergo hepatectomy, experience recurrence. Although the prognosis is poorer for patients with early recurrence (within 6 months...
Publication date: Available online 12 August 2019Source: European Journal of Surgical OncologyAuthor(s): Yasmin Jauhari, Melissa Ruth Gannon, David Dodwell, Kieran Horgan, Carmen Tsang, Karen Clements, Jibby Medina, Sarah Tang, Ruth Pettengell, David Alan CromwellAbstractVarious studies have documented variation in the management of older patients with breast cancer, and some of this variation stems from different approaches to balancing the expected benefit of different treatments, with the ability...
Publication date: Available online 12 August 2019Source: European Journal of Surgical OncologyAuthor(s): Bjoern Sander, Silke Cameron, Bastian Gunawan, Laszlo FüzesiAbstractBackgroundGastrointestinal stromal tumors (GIST) are the most frequent mesenchymal neoplasms of the gastrointestinal tract with highly variable potential for relapse. Tumor size and mitotic index (MI) are major risk factors that predict the outcome of GIST patients. Recent risk stratification schemes include some or all of the...
Mark above section as read
British Journal of Cancer, Published online: 14 August 2019; doi:10.1038/s41416-019-0550-2Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
British Journal of Cancer, Published online: 14 August 2019; doi:10.1038/s41416-019-0547-x16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot
British Journal of Cancer, Published online: 14 August 2019; doi:10.1038/s41416-019-0549-8p53 nuclear accumulation as an early indicator of lethal prostate cancer
Mark above section as read
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου